Literature DB >> 20446899

Protein tyrosine kinase pathway-derived ROS/NO productions contribute to G2/M cell cycle arrest in evodiamine-treated human cervix carcinoma HeLa cells.

Jia Yang1, Li-Jun Wu, Shin-Ichi Tashino, Satoshi Onodera, Takashi Ikejima.   

Abstract

A previous study indicated that reactive oxygen species (ROS) and nitric oxide (NO) played pivotal roles in mediating cytotoxicity of evodiamine in human cervix carcinoma HeLa cells. This study suggested that G2/M cell cycle arrest was triggered by ROS/NO productions with regulations of p53, p21, cell division cycle 25C (Cdc25C), Cdc2 and cyclin B1, which were able to be prevented by protein tyrosine kinase (PTK) activity inhibitor genistein or JNK inhibitor SP600125. The decreased JNK phosphorylation by addition of Ras or Raf inhibitor, as well as the increased cell viability by addition of insulin-like growth factor-1 receptor (IGF-1R), Ras, Raf or c-Jun N-terminal kinase (JNK) inhibitor, further demonstrated that the Ras-Raf-JNK pathway was responsible for this PTK-mediated signalling. These observations provide a distinct look at PTK pathway for its suppressive effect on G2/M transition by inductions of ROS/NO generations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20446899     DOI: 10.3109/10715762.2010.481302

Source DB:  PubMed          Journal:  Free Radic Res        ISSN: 1029-2470


  14 in total

1.  Apoptosis of human non-small-cell lung cancer A549 cells triggered by evodiamine through MTDH-dependent signaling pathway.

Authors:  Yanmei Zou; Xiaomin Qin; Hua Xiong; Feng Zhu; Tao Chen; Hongge Wu
Journal:  Tumour Biol       Date:  2015-02-05

2.  Activation of JNK contributes to evodiamine-induced apoptosis and G2/M arrest in human colorectal carcinoma cells: a structure-activity study of evodiamine.

Authors:  Chih-Chiang Chien; Ming-Shun Wu; Shing-Chuan Shen; Ching-Huai Ko; Chih-Hung Chen; Ling-Ling Yang; Yen-Chou Chen
Journal:  PLoS One       Date:  2014-06-24       Impact factor: 3.240

3.  Evodiamine inhibits PDGF‑BB‑induced proliferation of rat vascular smooth muscle cells through the suppression of cell cycle progression and oxidative stress.

Authors:  Xie Ge; Si-Yu Chen; Mei Liu; Ting-Ming Liang; Chang Liu
Journal:  Mol Med Rep       Date:  2016-10-05       Impact factor: 2.952

4.  NOS2 deficiency has no influence on the radiosensitivity of the hematopoietic system.

Authors:  Chengcheng Li; Yi Luo; Lijian Shao; Aimin Meng; Daohong Zhou
Journal:  Cell Biosci       Date:  2018-04-27       Impact factor: 7.133

Review 5.  Pharmacological actions of multi-target-directed evodiamine.

Authors:  Hui Yu; Hongwei Jin; Wuzhuang Gong; Zhanli Wang; Huaping Liang
Journal:  Molecules       Date:  2013-01-31       Impact factor: 4.411

6.  Evaluation of the Cardiotoxicity of Evodiamine In Vitro and In Vivo.

Authors:  Weifeng Yang; Lina Ma; Sidi Li; Kaiyu Cui; Lei Lei; Zuguang Ye
Journal:  Molecules       Date:  2017-06-09       Impact factor: 4.411

7.  Genistein attenuates vascular endothelial impairment in ovariectomized hyperhomocysteinemic rats.

Authors:  Panpan Zhen; Qian Zhao; Dandan Hou; Teng Liu; Dongqiao Jiang; Jinhong Duan; Lingqiao Lu; Wen Wang
Journal:  J Biomed Biotechnol       Date:  2012-11-06

8.  S100A8/A9 (calprotectin) negatively regulates G2/M cell cycle progression and growth of squamous cell carcinoma.

Authors:  Ali Khammanivong; Chengxing Wang; Brent S Sorenson; Karen F Ross; Mark C Herzberg
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

9.  A potential daidzein derivative enhances cytotoxicity of epirubicin on human colon adenocarcinoma Caco-2 cells.

Authors:  Yu-Li Lo
Journal:  Int J Mol Sci       Date:  2012-12-21       Impact factor: 5.923

Review 10.  Antiproliferative Effects of Alkaloid Evodiamine and Its Derivatives.

Authors:  Xu Hu; Dahong Li; Chun Chu; Xu Li; Xianhua Wang; Ying Jia; Huiming Hua; Fanxing Xu
Journal:  Int J Mol Sci       Date:  2018-10-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.